Linezolid May Be Alternative For Adjunctive Antitoxin Therapy In Adults Hospitalized With Invasive GAS Infection Receiving β-Lactam Therapy, Study Finds

Infectious Disease Advisor (12/13, Basilio) reported, “Linezolid may be an alternative for adjunctive antitoxin therapy in adults hospitalized with invasive group A streptococcal (GAS) infection receiving β-lactam therapy, according to results of a study.” The researchers said, “Given the variable clindamycin resistance among GAS isolates globally and the unclear potential of clindamycin to inhibit toxins from clindamycin-resistant strains, linezolid could be considered as acceptable first-line adjunctive therapy.” The findings were published in The Lancet Infectious Diseases.